- Lifecore Biomedical has entered a development services agreement with Indomo to provide CDMO support for the corticosteroid drug candidate DT-001.
- Lifecore will manufacture engineering and clinical batches of the therapy to support studies, preparing the program for Phase 2 clinical trials in 2026.
Lifecore Biomedical has entered into a development services agreement with Indomo to support the development of DT-001, a corticosteroid drug candidate designed to treat inflammatory acne lesions. The collaboration expands the relationship between the two companies, with Lifecore providing contract development and manufacturing services for the program.
Under the agreement, Lifecore will produce engineering and clinical batches of DT-001. These batches will support planned studies intended to prepare the product for anticipated advancement into Phase 2 clinical trials in 2026. The agreement follows an earlier engagement in which Lifecore conducted formulation and process optimization activities for the same program.
DT-001 is being developed for use with Indomo’s investigational ClearPen™ intradermal self-injection device. The system combines a proprietary injection device and microneedle with a formulation of triamcinolone acetonide to enable at-home administration for patients with inflammatory acne lesions.
“We are thrilled to continue to grow our relationship with Indomo and support a customer that possesses such high-quality leadership and ambitious plans for innovation.”
Paul Josephs, president and chief executive officer of Lifecore Biomedical
Indomo’s program aims to expand access to treatment for inflammatory acne, a condition affecting approximately 50 million people annually in the United States. The company is developing its device-enabled therapeutic approach to enable patients to administer treatment at home while advancing DT-001 toward clinical development.
